Abstract
Introduction
While the benefits of authorized generics to the branded industry are clearly
apparent, the attitude of the generics industry is determined by individual
company strategy. For those generics players that aggressively challenge
patents, authorized generics are a threat to revenues, while for other smaller
companies, authorized generics represent an opportunity to get to market
quickly and easily.
Scope of this research
- An overview of the authorized generics landscape, including drivers and
resistors for both branded and generics players.
- An insight into which branded and generics companies entered into
authorized generics agreements in the US between 2004 and 2008.
- Analysis of the extent of authorized generic market share capture during 2
years following launch, by brand value, therapeutic class, and dosage form.
- An overview into what the future holds for authorized generics, in the US
and Europe.
Research and analysis highlights
Given the benefits associated with own authorized generics, it is unsurprising
that these dominated the data-set under investigation, with the
Pfizer-Greenstone authorized generic combination by far the most frequent.
The authorized generic launched at a greater discount to the branded drug than
the conventional generic, in 65% of agreements under analysis, reflecting the
higher margins available to the authorized generics company which potentially
neither developed, manufactured, or obtained approval to market the drug.
The greatest number of generic entrants was associated with the highest value
branded products (with pre-generic quarterly sales in excess of $600m) in the
data-set under analysis, with this group showing an average of 14 and 19
competitors at 1 and 2 years post generics launch.
Key reasons to purchase this research
- Understand what authorized generics are, and the strategic motivations
which drive companies to use them.
- Understand the effect of brand value, therapeutic class, and dosage form
on the relative success of authorized generics to gain generics market share.
- Gain an insight into how the authorized generics landscape will evolve in
the future.
| 
View Cart
